Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308.
Fraile-Ribot PA, Del Rosario-Quintana C, López-Causapé C, Gomis-Font MA, Ojeda-Vargas M, Oliver A. Fraile-Ribot PA, et al. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e02112-19. doi: 10.1128/AAC.02112-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31685471 Free PMC article. No abstract available.
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Arca-Suárez J, Vázquez-Ucha JC, Fraile-Ribot PA, Lence E, Cabot G, Martínez-Guitián M, Lasarte-Monterrubio C, Rodríguez-Iglesias M, Beceiro A, González-Bello C, Galán-Sánchez F, Oliver A, Bou G. Arca-Suárez J, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3209-3217. doi: 10.1093/jac/dkaa291. J Antimicrob Chemother. 2020. PMID: 32728723
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G. Ruedas-López A, et al. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20. Antimicrob Agents Chemother. 2022. PMID: 34930034 Free PMC article.
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A. Arca-Suárez J, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01110-19. doi: 10.1128/AAC.01110-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31383659 Free PMC article.
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.
Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, Oliver A. Fraile-Ribot PA, et al. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e01117-17. doi: 10.1128/AAC.01117-17. Print 2017 Sep. Antimicrob Agents Chemother. 2017. PMID: 28674059 Free PMC article.
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Fraile-Ribot PA, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19. doi: 10.1128/AAC.02165-19. Print 2020 Jan 27. Antimicrob Agents Chemother. 2020. PMID: 31740559 Free PMC article.
31 results